DNTHHealthcare · BiotechnologyThe 14 Wall Street analysts covering Dianthus Therapeutics, Inc. hold a median 12-month price target of $132 — +18.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Dianthus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DNTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +18.8% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $130 → $158 |
| 6 Aug 2026 | Truist Securities | Maintains | Buy | $110 → $128 |
| 5 Aug 2026 | Wedbush | Maintains | Outperform | $105 → $122 |
| 3 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $120 → $134 |
| 6 May 2026 | Wedbush | Maintains | Outperform | — |
| 6 May 2026 | Wedbush | Maintains | Outperform | $103 → $105 |
| 9 Apr 2026 | Wolfe Research | Initiates | Outperform | — |
| 19 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 12 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 10 Mar 2026 | Baird | Maintains | Outperform | — |
| 10 Mar 2026 | Clear Street | Maintains | Buy | — |
| 10 Mar 2026 | Raymond James | Upgrade | Strong Buy | — |
| 10 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 9 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 4 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 11 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 2 Feb 2026 | Jefferies | Maintains | Buy | — |
| 8 Jan 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNTH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 1% of US stocks
Cheaper than 22% of US stocks
Cheaper than 90% of US stocks
Higher than 97% of US stocks
Higher than 93% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 29% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Dianthus Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Dianthus Therapeutics reported a Q2 loss of $0.90 per share, narrower than the Zacks Consensus Estimate of a $0.93 loss, compared with a $0.88 loss a year earlier. The company also topped revenue estimates for the quarter.
Why it matters — A DNTH watcher would care because the quarterly results came in better than analyst expectations on both loss per share and revenue.
Dianthus Therapeutics reported Q2 2026 financial results and updated progress across its pipeline, including the initiated Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (top-line results expected in 2H'28), interim responder data from the Phase 3 CAPTIVATE trial in CIDP (Part B guidance by YE'26), and an expanded MoMeNtum trial in MMN (top-line in December 2026). The company also reported progress on DNTH212 toward Phase 1 readouts by YE'26, DNTH312 targeting Phase 1 readiness by YE'27, and approximately $1.2 billion in cash providing runway into 2030.
Why it matters — A DNTH watcher would care because the update outlines near-term clinical catalysts across multiple programs—CIDP and MMN readouts by the end of 2026—alongside a cash position that funds operations into 2030.
Dianthus Therapeutics announced DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI for severe autoimmune diseases. In non-human primate studies it showed comparable aC1s inhibition and half-life to claseprubart and similar depth of Ig reductions versus povetacicept, with the company aiming for Phase 1 readiness by year-end 2027.
Why it matters — DNTH312 extends Dianthus' pipeline beyond neuromuscular disease into additional autoimmune indications by combining two complementary, validated disease-modifying pathways.
Dianthus Therapeutics announced that on August 3, 2026, it granted equity awards, described as inducement grants under NASDAQ Listing Rule 5635(C)(4), to six newly-hired, non-executive employees. The company is a clinical-stage biotechnology firm focused on treatments for severe autoimmune diseases.
Why it matters — A DNTH watcher would care because the inducement equity grants signal recent additions to the company's workforce, which is relevant to its operations as a clinical-stage biotech, though the announcement contains no business or financial updates.
The 14 Wall Street analysts covering Dianthus Therapeutics, Inc. have a median 12-month price target of $132, with estimates ranging from $109 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Dianthus Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dianthus Therapeutics, Inc. 60 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Dianthus Therapeutics, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +18.8% from the last close, and Ticker Nerd's factor model ranks Dianthus Therapeutics, Inc. 60 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Dianthus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $109 to $200 over the next 12 months.
Dianthus Therapeutics, Inc. returned +369.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases.
The most recent item we track (Zacks Investment Research, 4 Aug 2026): "Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates". Dianthus Therapeutics reported a Q2 loss of $0.90 per share, narrower than the Zacks Consensus Estimate of a $0.93 loss, compared with a $0.88 loss a year earlier. The company also topped revenue estimates for the quarter.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience compared to existing therapies, targeting validated immune pathways such as the classical complement pathway, plasmacytoid dendritic cells, and B cells. The company's lead candidate, DNTH103 (claseprubart), is a subcutaneous active C1s inhibitor in clinical trials for neuromuscular indications including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. DNTH212, a bifunctional fusion protein, addresses both innate and adaptive immune responses by reducing type 1 interferon production and suppressing B-cell function. Dianthus Therapeutics Inc. operates in the healthcare biotechnology sector, advancing investigational medicines aimed at transforming treatment options for immune-mediated conditions. Founded in 2019 and headquartered in New York, New York, with additional presence in Waltham, Massachusetts, the company is led by an experienced team of biotechnology and pharmaceutical executives.
CEO Mr. Marino Garcia M.B.A. · 78 employees · United States · https://dianthustx.com